| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ASTHAstrana Health, Inc. | 1.37B | 27.38 | 30.42 | 46.72% | 0.33% | 1.72% | 3.22% | 0.92 |
| PIIIP3 Health Partners Inc. | 10.85M | 3.30 | -0.06 | 18.48% | -9.07% | -6.92% | 1.11 | |
| AGLAgilon Health, Inc. | 422.87M | 1.02 | -1.62 | 40.41% | -5.24% | -100.71% | 0.09 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B |
| Revenue Growth % | - | 0.53% | 0.25% | 0.57% | 0.81% | 0.4% |
| Cost of Goods Sold | 765.9M | 1.12B | 1.46B | 2.28B | 4.25B | 6.06B |
| COGS % of Revenue | 0.96% | 0.92% | 0.96% | 0.95% | 0.98% | 1% |
| Gross Profit | 28.51M | 94.15M | 65.74M | 111.36M | 69.67M | 4.84M |
| Gross Margin % | 0.04% | 0.08% | 0.04% | 0.05% | 0.02% | 0% |
| Gross Profit Growth % | - | 2.3% | -0.3% | 0.69% | -0.37% | -0.93% |
| Operating Expenses | 135.09M | 150.82M | 437.99M | 216.74M | 301.8M | 296.97M |
| OpEx % of Revenue | 0.17% | 0.12% | 0.29% | 0.09% | 0.07% | 0.05% |
| Selling, General & Admin | 122.83M | 137.29M | 427.5M | 207.79M | 285.76M | 268.91M |
| SG&A % of Revenue | 0.15% | 0.11% | 0.28% | 0.09% | 0.07% | 0.04% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 12.25M | 13.53M | 10.48M | 8.95M | 16.04M | 28.06M |
| Operating Income | -106.57M | -56.67M | -372.24M | -105.38M | -232.13M | -292.13M |
| Operating Margin % | -0.13% | -0.05% | -0.24% | -0.04% | -0.05% | -0.05% |
| Operating Income Growth % | - | 0.47% | -5.57% | 0.72% | -1.2% | -0.26% |
| EBITDA | -65.16M | -42.57M | -357.57M | -91.61M | -211.97M | -267.67M |
| EBITDA Margin % | -0.08% | -0.03% | -0.24% | -0.04% | -0.05% | -0.04% |
| EBITDA Growth % | - | 0.35% | -7.4% | 0.74% | -1.31% | -0.26% |
| D&A (Non-Cash Add-back) | 41.41M | 14.1M | 14.67M | 13.77M | 20.16M | 24.46M |
| EBIT | -105.62M | -54.21M | -376.83M | -86.19M | -187.8M | -242.65M |
| Net Interest Income | -9.07M | -8.13M | -6.15M | -4.48M | -6.66M | -6.18M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.07M | 8.13M | 6.15M | 4.48M | 6.66M | 6.18M |
| Other Income/Expense | -8.11M | -5.67M | -10.73M | 14.71M | 37.67M | 43.3M |
| Pretax Income | -114.69M | -62.34M | -382.98M | -90.67M | -194.46M | -248.83M |
| Pretax Margin % | -0.14% | -0.05% | -0.25% | -0.04% | -0.05% | -0.04% |
| Income Tax | -232K | 865K | 886K | 1.64M | 791K | 1.45M |
| Effective Tax Rate % | 2.46% | 0.96% | 1.06% | 1.18% | 1.35% | 1.05% |
| Net Income | -282.59M | -60.05M | -406.49M | -106.55M | -262.6M | -260.15M |
| Net Margin % | -0.36% | -0.05% | -0.27% | -0.04% | -0.06% | -0.04% |
| Net Income Growth % | - | 0.79% | -5.77% | 0.74% | -1.46% | 0.01% |
| Net Income (Continuing) | -114.45M | -63.21M | -383.86M | -92.31M | -195.25M | -250.28M |
| Discontinued Operations | 0 | 3.16M | -22.93M | -14.55M | -67.55M | -9.82M |
| Minority Interest | 0 | 0 | -300K | -611K | -818K | 0 |
| EPS (Diluted) | -0.74 | -0.16 | -1.09 | -0.26 | -0.64 | -0.63 |
| EPS Growth % | - | 0.78% | -5.81% | 0.76% | -1.46% | 0.02% |
| EPS (Basic) | -0.74 | -0.16 | -1.09 | -0.26 | -0.64 | -0.63 |
| Diluted Shares Outstanding | 384.02M | 384.84M | 372.93M | 408.15M | 408.92M | 410.97M |
| Basic Shares Outstanding | 384.02M | 384.84M | 372.93M | 408.15M | 408.92M | 410.97M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 245.53M | 294.2M | 1.37B | 1.45B | 1.48B | 1.46B |
| Cash & Short-Term Investments | 123.63M | 106.8M | 1.05B | 877.2M | 495.1M | 405.6M |
| Cash Only | 123.63M | 106.8M | 1.05B | 465.3M | 114.33M | 193.86M |
| Short-Term Investments | 0 | 0 | 0 | 411.9M | 380.77M | 211.74M |
| Accounts Receivable | 93.25M | 144.56M | 293.41M | 492.36M | 942.46M | 1.02B |
| Days Sales Outstanding | 42.85 | 43.31 | 70.39 | 75.25 | 79.7 | 61.25 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 24.33M | 33.21M | 18.97M | 81.71M | 42.51M | 35.14M |
| Total Non-Current Assets | 157.27M | 152.16M | 219.06M | 246.19M | 260.79M | 276.21M |
| Property, Plant & Equipment | 18.84M | 16.04M | 20.9M | 31.95M | 40.99M | 36.95M |
| Fixed Asset Turnover | 42.18x | 75.95x | 72.80x | 74.74x | 105.31x | 164.01x |
| Goodwill | 41.54M | 41.54M | 0 | 2.51M | 24.13M | 24.13M |
| Intangible Assets | 71.15M | 60.47M | 96.94M | 18.45M | 63.77M | 72.77M |
| Long-Term Investments | 0 | 8.5M | 6.69M | 17.35M | 44.75M | 61.76M |
| Other Non-Current Assets | 25.74M | 25.61M | 94.53M | 175.93M | 87.15M | 80.6M |
| Total Assets | 402.79M | 446.36M | 1.59B | 1.7B | 1.74B | 1.73B |
| Asset Turnover | 1.97x | 2.73x | 0.96x | 1.41x | 2.48x | 3.50x |
| Asset Growth % | - | 0.11% | 2.55% | 0.07% | 0.03% | -0% |
| Total Current Liabilities | 199.61M | 266.83M | 356.96M | 535.09M | 977.16M | 1.15B |
| Accounts Payable | 188.26M | 260.11M | 348.65M | 478.23M | 968.06M | 1.15B |
| Days Payables Outstanding | 89.72 | 84.45 | 87.42 | 76.66 | 83.2 | 69.29 |
| Short-Term Debt | 3.04M | 3.04M | 8.31M | 5M | 9.1M | 2.46M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.31M | 3.68M | 0 | 51.87M | 0 | 0 |
| Current Ratio | 1.23x | 1.10x | 3.83x | 2.71x | 1.51x | 1.27x |
| Quick Ratio | 1.23x | 1.10x | 3.83x | 2.71x | 1.51x | 1.27x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 435.21M | 464.26M | 137.7M | 121.77M | 102.69M | 111.02M |
| Long-Term Debt | 67.14M | 64.67M | 43.4M | 38.48M | 32.31M | 34.9M |
| Capital Lease Obligations | 7.74M | 5.51M | 7.9M | 9.09M | 10.9M | 6.6M |
| Deferred Tax Liabilities | 12.82M | 10.01M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 347.51M | 384.07M | 86.39M | 74.19M | 59.48M | 69.52M |
| Total Liabilities | 634.82M | 731.09M | 494.66M | 656.86M | 1.08B | 1.26B |
| Total Debt | 77.92M | 73.21M | 59.61M | 52.57M | 52.31M | 43.96M |
| Net Debt | -45.71M | -33.58M | -995.21M | -412.73M | -62.02M | -149.9M |
| Debt / Equity | - | - | 0.05x | 0.05x | 0.08x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -11.75x | -6.97x | -60.57x | -23.50x | -34.87x | -47.29x |
| Total Equity | -232.03M | -284.73M | 1.09B | 1.04B | 661.02M | 470.95M |
| Equity Growth % | - | -0.23% | 4.83% | -0.05% | -0.36% | -0.29% |
| Book Value per Share | -0.60 | -0.74 | 2.93 | 2.55 | 1.62 | 1.15 |
| Total Shareholders' Equity | -232.03M | -284.73M | 1.09B | 1.04B | 661.84M | 470.95M |
| Common Stock | 2.47M | 2.49M | 4M | 4.12M | 4.06M | 4.12M |
| Retained Earnings | -491.14M | -551.19M | -957.68M | -1.06B | -1.33B | -1.59B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -5.56M | -2.3M | -88K |
| Minority Interest | 0 | 0 | -300K | -611K | -818K | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -103.86M | -53.2M | -148.16M | -130.81M | -156.2M | -57.78M |
| Operating CF Margin % | -0.13% | -0.04% | -0.1% | -0.05% | -0.04% | -0.01% |
| Operating CF Growth % | - | 0.49% | -1.78% | 0.12% | -0.19% | 0.63% |
| Net Income | -282.74M | -60.05M | -406.79M | -106.86M | -262.8M | -260.1M |
| Depreciation & Amortization | 41.41M | 14.1M | 14.67M | 13.77M | 20.16M | 24.46M |
| Stock-Based Compensation | 5.22M | 6.69M | 292.39M | 28.38M | 69.33M | 50.66M |
| Deferred Taxes | -16.18M | -2.81M | -3.23M | 532K | 0 | 0 |
| Other Non-Cash Items | 115.24M | -17.6M | 9.82M | -7.19M | 27.18M | -3.38M |
| Working Capital Changes | 33.18M | 6.47M | -55.02M | -59.44M | -10.07M | 130.59M |
| Change in Receivables | -23.28M | -59.38M | -149.04M | -204.17M | 0 | -74.58M |
| Change in Inventory | 0 | 0 | 149.04M | 0 | 0 | 0 |
| Change in Payables | 38.26M | 67.31M | 95.7M | 173.45M | 473.61M | 198.58M |
| Cash from Investing | -5.06M | 22.07M | -90.51M | -444.39M | -44.02M | 139.89M |
| Capital Expenditures | -3.91M | -2.35M | -13.43M | -15.43M | -15.83M | -13.25M |
| CapEx % of Revenue | 0% | 0% | 0.01% | 0.01% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -1.15M | -1.79M | -75.74M | -23.75M | -34.51M | -41.77M |
| Cash from Financing | 176.3M | 24.62M | 1.15B | 28.06M | -193.13M | -2.58M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | -303K | 0 | -14.74M | 0 | 11.87M | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -107.77M | -55.55M | -161.59M | -163.47M | -187.01M | -71.03M |
| FCF Margin % | -0.14% | -0.05% | -0.11% | -0.07% | -0.04% | -0.01% |
| FCF Growth % | - | 0.48% | -1.91% | -0.01% | -0.14% | 0.62% |
| FCF per Share | -0.28 | -0.14 | -0.43 | -0.40 | -0.46 | -0.17 |
| FCF Conversion (FCF/Net Income) | 0.37x | 0.89x | 0.36x | 1.23x | 0.59x | 0.22x |
| Interest Paid | 0 | 7.09M | 4.82M | 3.67M | 5.8M | 4.6M |
| Taxes Paid | 0 | 2K | 1.82M | 5.31M | 5.36M | 1.8M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -100.76% | -9.99% | -30.86% | -45.96% |
| Return on Invested Capital (ROIC) | - | - | -289.64% | -21.82% | -28.38% | -47.63% |
| Gross Margin | 3.59% | 7.73% | 4.32% | 4.66% | 1.61% | 0.08% |
| Net Margin | -35.57% | -4.93% | -26.72% | -4.46% | -6.08% | -4.29% |
| Debt / Equity | - | - | 0.05x | 0.05x | 0.08x | 0.09x |
| Interest Coverage | -11.75x | -6.97x | -60.57x | -23.50x | -34.87x | -47.29x |
| FCF Conversion | 0.37x | 0.89x | 0.36x | 1.23x | 0.59x | 0.22x |
| Revenue Growth | - | 53.36% | 24.88% | 56.97% | 80.74% | 40.41% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Medical Services | - | - | - | 6.05B |
| Medical Services Growth | - | - | - | - |
| Other Operating | - | - | - | 12.81M |
| Other Operating Growth | - | - | - | - |
| Medical Services Revenue | - | - | 4.31B | - |
| Medical Services Revenue Growth | - | - | - | - |
| Product and Service, Other | - | - | 9.01M | - |
| Product and Service, Other Growth | - | - | - | - |
| Medical Services Revenue1 | 6.41M | 511K | - | - |
| Medical Services Revenue1 Growth | - | -92.03% | - | - |
| Other Operating Revenue1 | 36K | 14K | - | - |
| Other Operating Revenue1 Growth | - | -61.11% | - | - |
Agilon Health, Inc. (AGL) reported $5.89B in revenue for fiscal year 2024. This represents a 641% increase from $794.4M in 2019.
Agilon Health, Inc. (AGL) grew revenue by 40.4% over the past year. This is strong growth.
Agilon Health, Inc. (AGL) reported a net loss of $308.3M for fiscal year 2024.
Agilon Health, Inc. (AGL) has a return on equity (ROE) of -46.0%. Negative ROE indicates the company is unprofitable.
Agilon Health, Inc. (AGL) had negative free cash flow of $98.5M in fiscal year 2024, likely due to heavy capital investments.